Gale and Ira Drukier Institute for Children's Health

You are here

Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma.

TitleIdentification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma.
Publication TypeJournal Article
Year of Publication2019
AuthorsMusselman K, Glynn S, Mosquera JMiguel, Elemento O, Sboner A, Beltran H, Holcomb K
JournalGynecol Oncol Rep
Volume28
Pagination54-57
Date Published2019 May
ISSN2352-5789
Abstract

Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/ fluorescence hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response.

DOI10.1016/j.gore.2019.01.013
Alternate JournalGynecol Oncol Rep
PubMed ID30906838
PubMed Central IDPMC6411491